Energometabolic composition for preventive therapy of metabolic acidosis, ketosis, and iodine deficiency in cows
SUBSTANCE: claimed energometabolic composition for preventive therapy contains beet molasses, succinic acid and citric acid, sodium chloride, iodinol in aqueous solution in the following ratio, wt %: succinic acid - 1,5, citric acid - 0,15, beet molasses - 50, sodium chloride - 2,5, iodinol - 5,0, water - the rest The claimed method involves the use of the claimed composition with the multiplicity of once in 5-7 days by watering animals at a dilution of the composition in water of 1:5-7 or mixing it with the fodder.
EFFECT: group of inventions relates to the field of veterinary medicine and is intended for the prevention of metabolic acidosis, ketosis, and hypothyroidism in cows.
2 cl, 4 tbl, 1 ex
SUBSTANCE: invention represents a method for preparing a sterile nanoemulsion of perfluororganic compounds (PFOC) involving: adding a PFOC mixture to an aqueous solution of a stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce a PFOC pre-emulsion; mixing the PFOC pre-emulsion with a salt-water solution to produce the PFOC nanoemulsion; keeping the PFOC nanoemulsion at a temperature from 2 to 10°C for at least 18 hours. The method can be also implemented as follows: pre-filling a circulation loop of a PFOC nanoemulsion generating plant with the aqueous solution of the stabilising agent; adding the PFOC mixture to the aqueous solution of the stabilising agent; homogenising the PFOC mixture with the aqueous solution of the stabilising agent to produce the PFOC pre-emulsion; mixing the PFOC pre-emulsion with the salt-water solution to produce the PFOC nanoemulsion.
EFFECT: higher stability of the PFOC emulsion and prolonging the storage life.
30 cl, 7 ex, 5 tbl, 1 dwg
SUBSTANCE: for patient with alimentary obesity preliminarily determined are: clearance of osmotically free water (CFW) and colloid oncotic pressure (COP). If CFW level is lower than -0.45 ml/min and COP is lower than 18 mm Hg, therapy starts from intravenous introduction of 6% HES "Voluven" in dose 6.5 ml/kg/day at rate 350 ml/h. Immediately after the end of infusion introduction with syringe doser of 25% solution of magnesium sulphate in dose 0.75 ml/kg/day at rate 2.8 ml/h. For patient without obesity, if CFW level is lower than -0.6 ml/min and COP is lower than 21 mm Hg, therapy is started from intravenous introduction of 6% HES "Voluven" in dose 5.5 ml/kg/day at rate 300 ml/h. 25% solution of magnesium sulphate in dose 0.9 ml/kg/day at rate 2.4 ml/h is also introduced by means of syringe doser. Treatment is carried out during a day.
EFFECT: carrying out adequate therapy in said category of patients due to selection of mode of introduction of preparations, conditioning fast recovery of kidney function.
2 cl, 2 ex
SUBSTANCE: invention represents a balanced infusion solution containing sodium, potassium and magnesium chlorides, a solvent and sodium L-arginine succinate of formula: Na+[NH=C(NH2)NH(CH2)3CH(NH2)COOH]+[OOC(CH2)2COO]2-. The ingredients in the solution are found in certain proportions, wt %.
EFFECT: invention provides enhanced detoxification activity, low toxicity and wide range of clinical applications.
11 tbl, 6 ex
SUBSTANCE: body weight, physiological requirements and degree of disease severity are determined. That is followed by calculating an infusion therapy extent by formula: V=Ce×BW+PR+300 ml 5% glucose, wherein V is the infusion therapy extent, ml; Ce is an encephalopathy coefficient: 0.02 in prodromal period, 0.03 in manifested psychosis, 0.04 in chronic alcoholic encephalopathy; BW is patient's body weight, gram; PR are the physiological requirements for one day, ml.
EFFECT: method provides the effective infusion therapy in the given category of patients by the accurate determination of the therapy extent caused by taking into account the stages of alcoholic encephalopathy development.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and consists in a pharmaceutical substance, representing an instantly soluble in water powder of a crystalline chemical compound of dextrose with sodium chloride - (C6H12O6)2·NaCl·H2O, which has a specific rotation of a polarised light plane initial at 113°, equilibrium at 52.9°, constant of the mutarotation rate of 6.7·10-3 and moisture content of not more than 4.3%. The invention also relates to a method of obtaining the pharmaceutical substance.
EFFECT: pharmaceutical substance has stable quality, is easily packaged, it is possible to prepare a solution for injections from it in a fast and easy way, its storage and transportation are considerably more simple.
2 cl, 1 ex
SUBSTANCE: invention refers to medicine, namely to anaesthetics, and can be used for the prevention of spinal headache during spinal or combined spinal epidural anaesthesia in bone marrow exfusion. That is ensured by an intravenous infusion of 6% hydroxyethylstarch 500 ml 30 minutes before the subarachnoid puncture and the spinal and combined spinal epidural puncture or for the first 30 minutes of the anaesthesia.
EFFECT: invention provides preventing postoperative spinal headache in this group of patients.
1 dwg, 1 tbl, 4 ex
SUBSTANCE: invention refers to medicine, namely to cardiovascular surgery, and concerns preventing a diffuse intra- and postoperative blood loss in surgery of abdominal aorta. To this effect, performing the aortoiliac operations is combined with measuring preoperative antithrombin III; if the measured value is less than 87±3%, a thromboelastography is performed from the moment of an anaesthetic support started with determining a coagulation index. If the coagulation index is less than 2.89±0.25 as early as at the start of the stage of approaching the abdominal aorta, before any surgically significant blood loss, fresh-frozen plasma of the identical group in a min. amount of 600 ml is administered into the patient. If the following dynamic control shows a decrease of the coagulation index below 1.10±0.28, at least 600 ml of fresh-frozen plasma is additionally administered, providing thereby the coagulation index by the end of the operation not less than 0.52±0.27.
EFFECT: method provides effective prevention of intra- and postoperative blood loss by prevention of intraoperative homeostatic disorders.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a concentrated acidic component for producing a hemodialysis solution. The acidic component contains the following ingredients in an amount of producing 1 litre of the solution in water purified for hemodialysis: 204.7-215.0 g of sodium chloride NaCl, 6.2-9.0 g of calcium chloride CaCl2*2H2O, 3.56-7.12 g of magnesium chloride MgCl2*6H2O, 5.22-10.44 g of potassium chloride KCl, 0.021-6.28 g of acetic acid and 0.02-6.2 g of succinic acid. Also, the invention refers to the hemodialysis solution containing the above concentrated acidic component, water purified for hemodialysis, and bicarbonate component. The invention also refers to a method for producing the hemodialysis solution with the method involving supplying the concentrated acidic component into a hemodialysis apparatus, diluting with water purified for hemodialysis, and mixing with bicarbonate component. What is also declared is a kit for producing the concentrated acidic component containing sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid in the form of dry agents and acetic acid in the form of a liquid agent.
EFFECT: invention provides higher effectiveness by a biochemical compatibility with blood plasma of the hemodialysis solution.
36 cl, 18 tbl, 16 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a composition, adapted for intravenous introduction, intended for the treatment or prevention of pathological processes of crystallisation or calcification in a person, subjected to dialysis. The composition contains inositol phosphate and/or its pharmaceutically acceptable salt, with a dose of inositol phosphate and/or its salt constituting from 1 nmol/kg to 0.1 mil/kg. The invention also relates to a combined method of treatment, including the intravenous introduction of the said composition of the dialysis liquid simultaneously.
EFFECT: method is intended for the treatment or prevention of pathological processes, associated with an impairment of the regulation of physiologically adequate levels of inositol phosphate in blood plasma of the person, subjected to dialysis.
10 cl, 4 dwg, 1 tbl, 9 ex
SUBSTANCE: what is declared is an infusion solution for filling the deficiency and meeting the physiological needs for water and basic electrolytes, which contains the following ingredients: sodium (Na+) - 27.72-28.28 mmole/l; fumarate(H2C4O4 2-) - 13.86-14.14 mmole/l; potassium (K+) - 18.61-18.99 mmole/l; calcium (Ca2+) - 3.56-3.64 mmole/l; magnesium (Mg2+) - 2.18-2.22 mmole/l; chlorine (Cl-) - 30.0-30.6 mmole/l; glucose (C6H12O6) - 189.1-192.9 mmole/l, water for injections.
EFFECT: solution contains the basic electrolyte concentration balanced for meeting the physiological needs; it is safe for the clinical application and can be used in diseases of various aetiology for patients of any age.
1 tbl, 2 ex
SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for treating trophic ulcers and purulonecrotic involvements of lower extremities in diabetic patients. That requires a baseline therapy and a regional fibrinolytic therapy. Conducting the regional fibrinolytic therapy following applying a rubber bandage on the lower one-third of the shin is accompanied by administering Urokinase medac in a dose of 100 thousand units into the heel bone once a day within 5 days.
EFFECT: in the setting of reducing the total dosage of the preparation, the invention enables providing the high concentration of Urokinase medac in a pathological centre, improving microcirculation and metabolic processes in the involved tissues, accelerating the wound healing and reducing the length of hospital admission of the patients suffering from diabetic foot syndrome.
SUBSTANCE: invention refers to medicine, namely to treating diseases related to insulin resistance. A method of treating involves administering an effective amount of IL-17A and/or IL-17F antagonist, wherein the above agonist represents an antibody or its antigen-binding fragment. The group of inventions also refers to a pharmaceutical composition containing the IL-17A and/or IL-17F antagonist with a pharmaceutically acceptable additive added, and to a set containing the above agonist, and an administration instruction.
EFFECT: using the given group of inventions enables reducing the insulin resistance in an individual by administering pro-inflammatory factors IL-17A and/or IL-17F antagonists.
20 cl, 3 ex, 14 dwg
SUBSTANCE: what is presented is a fused protein that is a Notch1 antagonist, which consists of a human Fc region fused with the EGF-like repeat 1-13 of Notch1 or the EGF-like repeat 1-24 of Notch1. Fc-portion is localised on a carboxy-terminal portion of the EGF-repeat. There are described a pharmaceutical composition for the protein-based Notch signal transmission inhibition and using it for preparing the pharmaceutical composition for treating an individual suffering from: tumour; ovarian cancer; metabolic disorder; vascular proliferative retinopathy. What is presented is using the fused protein for producing the pharmaceutical composition for inhibition: angiogenesis in the individual; physiological lymphangiogenesis or pathological lymphangiogenesis in the individual; tumour deposits in the individual.
EFFECT: using the invention provides the proteins expressed in a supernatant at a level by several times more than the fused protein containing the EGF-like repeats 1-36 of Notch1; they penetrate into the tumour better, maintain a ligand-binding ability with the fused protein containing the repeats 1-24, binds to DLL4 and JAG1, whereas the fused protein containing the repeats 1-13 only binds to DLL4, but not to JAG1 that can find application in therapy of various diseases related to the Notch1 activity.
18 cl, 124 dwg, 10 ex
SUBSTANCE: therapeutic agent containing activated-potentiated forms of anti-histamine, anti-tumour necrosis factor alpha (anti-TNF - α) and anti-S-100 brain specific antibodies is administered.
EFFECT: treating functional bowel disorders by ensuring the spasmolytic action and normalising the motor-evacuation function of the intestine.
11 cl, 4 ex, 4 tbl
SUBSTANCE: method includes carrying out drug treatment, diet therapy, physical exercise, balneotherapy. Drug treatment includes intake of an ACE inhibitor or a beta-blocker 30-40 minutes before the first breakfast. 2-2.5 hours after supper methmorphine in a dose of 500-1000 mg/day is taken in. Diet therapy includes fractional feeding with the calorie content of 1200 kilocalories from Monday to Friday. On Saturday the calorie content is reduced to 800-900 kilocalories, and on Sunday - to 600-700 kilocalories. The physical exercise is carried out in the form of walking in a slow tempo, with stops, with the total duration of 90-120 minutes. Balneotherapy is started with carrying out in the morning of a rain fresh water shower. Then, manual superficial massage of the neck zone is carried out. Baths take place in the period from 12 to 17 o'clock. For their carrying out hydrocarbonate-sulfate-sodium mineral water from Belokurikha resort with an increased content of silicic acid and fluorine, and mineralisation of 0.4 g/l is applied. Radon concentration for bath realisation constitutes 3.9-4.6 nCi/dm3, water temperature is 36-37°C. The duration of the bath time is five minutes on the first day, on the second day - eight minutes, on the third day - ten minutes, on the fourth day - rest, on the fifth and sixth days - twelve minutes, on the seventh day - fifteen minutes, on the eighth day - rest, on the following three days the baths are being carried out for 15 minutes.
EFFECT: method increases remission duration due to an increase of the non-specific resistance of the organism protection factors, normalisation of oxygenation and metabolic processes in tissues.
4 cl, 2 tbl, 2 ex
SUBSTANCE: present invention refers to fumaryldiketopiperazine (FDKP) microparticles applicable for pulmonary delivery and having a specific surface area within the range of 15 m2/g to 67 m2/g and a diameter within the range of 0.5 mcm to 10 mcm. The invention also refers to a dry powder comprising said microparticles that is also applicable for pulmonary delivery, to an inhalation system comprising a powder inhalation apparatus and the above dry powder, as well as to a method for delivering an active agent being an ingredient of the dry powder by inhalation of the above dry powder. There are also disclosed methods for forming the FDKP microparticles, first of which comprises dissolving FDKP in aqueous ammonia, adding an acidic solution to aqueous ammonia at temperature up to 12°C to 26°C and collecting a precipitate containing the FDKP microparticles after rinsing with deionised water. A second method for forming the FDKP microparticles involves supplying equal portions of 10.5 wt % of an acetic acid solution and 2.5 wt % of a FDKP solution at temperature 14-18°C through a high-shear mixer.
EFFECT: invention aims at preparing the FDKP microparticles applicable for pulmonary delivery that have the good aerodynamic performance and provide the enhanced drug absorption.
18 cl, 4 tbl, 9 dwg, 2 ex
SUBSTANCE: invention refers to a pharmaceutical tablet for oral administration containing ulipristal acetate 3-18 wt %; a diluent 60 - 95 wt % specified in lactose monohydrate, microcrystalline cellulose, cellulose, mannitol and combinations thereof; a binding agent 0 - 10 wt % specified in hydroxypropyl methyl cellulose, povidone and combinations thereof; sodium croscarmellose 1 - 10 wt % and magnesium stearate 0.5 - 4 wt %.The invention also refers to a method for preparing the above tablet which involves mixing the ingredients and forming the tablet by wet granulation or direct compression.
EFFECT: invention provides the new formulation of the tablet with improved disintegration.
13 cl, 2 dwg, 5 tbl, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: microparticle contains an agglomerate of particles containing a hydrophilic active substance, wherein the particle contains an amphiphilic polymer composed of a hydrophobic segment of polyhydroxy acid and a hydrophilic segment of polysaccharide or polyethylene glycol, and a hydrophilic active substance. What is also disclosed is a method of producing the agglomerated microparticles, which involves (a) a stage of preparing a reverse phase emulsion, (b) a stage of preparing a solid residue containing the hydrophilic active substance, and (c) a stage of introducing the solid residue into a liquid phase containing a surface modifier.
EFFECT: agglomerated microparticles provide the effective encapsulation of the hydrophilic active substance and the release of the hydrophilic active substance at an appropriate speed.
14 cl, 22 dwg, 4 tbl, 31 ex
SUBSTANCE: medicinal agent for inhibition of MASP-2-dependent complement is an agent containing an antibody or its fragment, bound with a full-size polypeptide MASP-2, but not bound with a MASP-2 N-terminal fragment containing CUBI-EGF-CUBII domains and not bound with a MASP-2 C-terminal fragment, containing of CCPII-SP domains.
EFFECT: invention makes it possible to selectively inhibit MASP-2-dependent activation of complement, at the same time leaving Clq-dependent classic path of complement activation as functionally unaffected.
9 cl, 39 dwg, 7 tbl, 31 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to combinations of peptides in each case with the same sequence length (SEQL) which can be prepared in a stable reproducible quality and quantity of a mixture (A) containing a number of x amino acid with protected acid groups or a number of z peptides with the acid groups protected by the protective groups and the activated amino groups, with the amino acids in the mixture (A) found in a specific molar ratio, and a mixture (B), containing a number of y amino acids with the amino groups protected by the protective groups, with a molar ratio of the amino acids of the mixture (B) being the same as the molar ratio of the amino acids of the mixture (A), and the number x=y, and x is a figure from 11 to 18.
EFFECT: new combinations of the peptides are presented.
13 cl, 2 dwg, 1 ex
SUBSTANCE: product contains drinking water having an oxidation-reduction potential from minus 600 to minus 50 mV, total mineralisation from 25 to 130 mg/l and pH value from 6.9 to 8.3. A method for producing a lymphatic drainage stimulant involves the advanced treatment of the drinking water by passing it through a semi-permeable membrane having a hole size of 0.0001-0.005 mcm, and the molecular hydrogen saturation of the water under pressure.
EFFECT: implementing the invention is expected to the highly effective and systemic stimulation of the lymphatic drainage of body tissues by intensifying lymph formation and transport accompanied by no adverse irritant effects.